Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?
Open Access
- 27 October 2024
- journal article
- review article
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-18
Abstract
T helper (Th) 17 cells, a distinct subset of Th lymphocytes, are known for their prominent interleukin (IL)-17 production and other pro-inflammatory cytokines. These cells exhibit remarkable plasticity, allowing them to exhibit different phenotypes in the cancer microenvironment. This adaptability enables Th17 cells to promote tumor progression by immunosuppressive activities and angiogenesis, but also mediate anti-tumor immune responses through employing immune cells in tumor setting or even by directly converting toward Th1 phenotype and producing interferon-gamma (IFN-γ). This dual role of Th17 cells in cancer makes it a double-edged sword in encountering cancer. In this review, we aim to elucidate the complexities of Th17 cell function in cancer by summarizing recent studies and, ultimately, to design novel therapeutic strategies, especially targeting Th17 cells in the tumor milieu, which could pave the way for more effective cancer treatments.Keywords
This publication has 218 references indexed in Scilit:
- Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinomaCancer Medicine, 2021
- Expression of Concern: Th17 and Treg cells function in SARS‐CoV2 patients compared with healthy controlsJournal of Cellular Physiology, 2020
- A catch‐22: Interleukin‐22 and cancerEuropean Journal of Immunology, 2018
- mTORC1 signaling and IL‐17 expression: Defining pathways and possible therapeutic targetsEuropean Journal of Immunology, 2015
- Association between Th17‐related cytokines and risk of non–small cell lung cancer among patients with or without chronic obstructive pulmonary diseaseCancer, 2015
- Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL‐17A expression and invasiveness of the tumorEuropean Journal of Immunology, 2013
- Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3Hepatology, 2011
- Human tumor‐infiltrating Th17 cells have the capacity to differentiate into IFN‐γ+ and FOXP3+ T cells with potent suppressive functionEuropean Journal of Immunology, 2011
- Prognostic impact of tumour‐infiltrating Th2 and regulatory T cells in classical Hodgkin lymphomaHematological Oncology, 2008
- International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates risingInternational Journal of Cancer, 2005